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Abstract
Lupus nephritis is associated with urinary protein excretion, hypoalbuminemia, and renal function
declines, which may impact the pharmacokinetics (PK) of mycophenolic acid (MPA).
The primary study objective was to evaluate and describe the PK of MPA and its glucuronide
(MPAG) in lupus nephritis. Secondary objectives were to determine the single and/or multiple effects
of clinical parameters (urinary protein excretion, serum albumin, and creatinine clearance) and
demographic variables (age, race, and gender) on total and unbound MPA and MPAG PK.
Plasma and urine were collected for 24-hours and assayed by HPLC with UV detection.
Noncompartmental PK analysis was performed using WinNonlin v4.1. Statistics included descriptive
analyses, urivariate and multiple regression tests, and T-test or nonparametric equivalent.
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Time to maximal concentration (0.5 to 8 hrs) was variable. Unbound MPA was 2.6±1.9% and oral
clearance (Cl/F 343 ± 200 mL/min) was ~ 2-fold higher than previously reported. Multiple regression
showed MPA Cl/F was predicted by creatinine clearance (Clcr) and serum albumin (MPA lnCl/F =
5.358 + 0.0092 (Clcr) − 0.078 (ranked albumin), R2 51.1%, p = 0.0195). UP:Cr ≥ 1 g/d had lower
trough and area under the curve (AUC 0-12) and higher Cl/F versus UP:Cr < 1 g/d. Serum albumin
< 4 g/dL had higher MPA Cl unbound and MPAG Clr 0-12 versus serum albumin ≥ 4g/dL. Recycling
AUC (AUC6-12) and equally gender and age predicted renal clearance of MPAG.
Clcr and serum albumin were identified as primary contributors to MPA exposure and should be
considered when evaluating dosages. The results of future studies should clarify the interactions of
other variables on drug exposure and treatment responses. Clinicians need to be mindful of clinical
changes that occur throughout the course of lupus nephritis in order to maintain efficacy and reduce
toxicity from MPA therapy.
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Introduction
Mycophenolic acid (MPA) has been used as an immunosuppressant agent to prevent renal
transplant rejection since 1995. As there is inherent variability in mycophenolic acid
pharmacokinetics within transplant patients, several researchers have sought to describe
mycophenolic acid variations that occur from the early post-transplant period to several months
after transplant.1-3 More recently, it has been suggested that therapeutic plasma monitoring of
mycophenolic acid may help to improve immunosuppressive outcomes. 4 Area under the
plasma concentration time curve from 0 to 12 hours (AUC 0-12) of 30 to 60 mcg h/L and trough
plasma concentrations (Ctr) of 1 to 3.5 mcg/mL are suggested as targets for combination
immunosuppressive therapy (MPA plus cyclosporine and steroids) in renal and heart transplant
patients. 4-5 These concentrations are based on high performance liquid chromatography
(HPLC) assays. Target ranges for MPA in single or double agent therapies or for use in
autoimmune diseases have not been established.
Since 1999, mycophenolic acid therapy has been evaluated for efficacy in patients with lupus
nephritis. 6-9 Similar to renal transplant recipients, glomerular disease patients often have
diminished renal function manifest as reductions in glomerular filtration rate (Clcr). However,
glomerular disease patients also commonly have protein in the urine and alterations in serum
albumin. Both urinary protein and decreased serum albumin (in addition to altered Clcr)
conceivably could lead to pharmacokinetic alterations of highly protein bound drugs such as
MPA in patients with glomuerulonephritis. Hence, a comprehensive evaluation of total and
free MPA pharmacokinetics in lupus nephritis patients on stable therapy is warranted. Analyses
of the impact of alterations in urinary protein, serum albumin, and Clcr on pharmacokinetics
could provide patient-specific factors that may be important for individualized dosing.
The primary purpose of this study was to evaluate the total and free pharmacokinetics of MPA
and its phenolic O-glucuronide (MPAG) in patients with lupus nephritis. The secondary
objectives were to determine the effects of clinical parameters (urinary protein excretion
(UP:Cr), serum albumin, and Clcr) and demographic variables (age, race, gender) on total and
unbound MPA and MPAG pharmacokinetics.
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Patients with biopsy confirmed lupus nephritis receiving maintenance therapy with MPA were
evaluated for study enrollment. Patients were required to be on a stable MPA dose for at least
two weeks. Concomitant therapy with other immunosuppressants was allowed and recorded.
Patients were fasting at study initiation and were fed a standard diet in the research unit
throughout the study period. The following clinical data was measured at the time of the study
or abstracted from the medical record: Clcr, UP:Cr, serum albumin, and serum creatinine. The
study and consent form was approved by the University’s Institutional Review Board and
patient consent was required prior to participation.
Pharmacokinetic Study
Patients were admitted to the General Clinical Research Unit (GCRC) to participate in a 24-
hour inpatient stay for pharmacokinetic analysis. Baseline blood was drawn for a trough plasma
concentration. The patients were then instructed to take their morning oral dose of MPA.
Additional plasma samples (7.5 mL) were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours.
Urine was collected during the following intervals: 0-6, 6-12, and 12-24 hours into acidified
(15 mL 6 N HCl) collection containers. Heparinized blood samples were immediately
centrifuged for 10 minutes at 4C, plasma transferred to plastic screw top tubes and stored at
-80 until assay. Urine volume for each collection time period was recorded, and 2 mL aliquots
were stored at -80C until assay. Unbound plasma fraction was determined by filtration via a
Centrifree® Micropartition device (Millipore, Ireland) with a filter cut-point of 30,000 daltons.
Temperature and centrifugation conditions were optimized to enable filtration of 10% of the
total plasma volume. The unbound fraction was assessed at the time point corresponding to
the Cmax and evaluated in spiked plasma separately. The unbound concentrations were then
calculated as unbound fraction multiplied by total concentration. Linearity of binding
throughout the evaluated concentration ranges was assumed. Samples were assayed by HPLC
using a variation on the methods of Wiwattanawongsa, et al 10, using methanol-formic acid
0.1% isocratic mobile phase (52:48) at a flow rate of 1.0 mL/min, suprofen as the internal
standard, and UV detection at 250 nm. The HPLC system consisted of a Hewlett-Packard series
1050 pump/injector, Hewlett-Packard Series 1050 UV detector, and Axxiom ODS column
(150 × 4.6 mm I.D., 5 micrometers). Plasma and urine standard curves for MPA were linear
over the range of 0.2-200 mcg/mL and 1-50 mcg/mL, respectively. Plasma and urine standard
curves for MPAG were linear over the range of 1-50 mcg/mL and 5-1500 mcg/mL,
respectively. MPAG concentrations were represented in terms of MPA-equivalents by
multiplying each MPAG concentration by 0.646 (molecular mass of MPA to MPAG) and
reported in mcg/mL. The amount of MPA available from a dose of the prodrug was estimated
as 72% of the dose (molecular mass of MPA to MPA mofetil). This calculation was used to
determine the amount of drug excreted in the urine in reference to the dose of MPA actually
administered from mycophenolate mofetil.
Pharmacokinetic Analysis
Noncompartmental pharmacokinetic analysis of total and unbound MPA and MPAG was
conducted using WinNonlin v4.1 (Pharsight, Mountain View CA) linear up-log down for AUC
determination. The following parameters were reported: concentration maximum (Cmax), time
to maximum concentration (Tmax), concentration trough (Ctr) at 12 and 24 hours, area under
the plasma concentration time curve from 0-12 hours (AUC 0-12), oral clearance (Cl/F), renal
clearance (Clr), and mean residence time (MRT). For the purpose of pharmacokinetic
evaluations we made the assumption that F = 1, since others have reported bioavailability of
close to 1. 2 AUC 12-24 and AUC 6-12 were calculated. The AUC 6-12 was used to estimate
entero-hepatic recycling as performed by others. 11-12 Urine analysis was performed by
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multiplying the concentration by volume for each collection period (0-6, 6-12, and 12-24).
Amount excreted in the urine (Ae) was computed for the 0-12 hour time frame by adding the
Ae for the first two collection intervals. Clr for the 0-12 hour time frame was calculated by
Ae 0-12/ AUC 0-12.
Statistics
Descriptive analyses for pharmacokinetic parameters, demographic variables and laboratories
included means, standard deviations, and medians as appropriate. Univariate assessments of
the key clinical characteristics (serum albumin, UP:Cr, Clcr, age, race, gender, steroid dose)
versus each pharmacokinetic parameter of interest (MPA Cl/F, MPA Clr, MPA unbound
clearance (Clunb), MPAG Clr, MPA AUC 0-12, MPA AUC 6-12, MPAG AUC 0-12) were
assessed by Spearman Rank correlations. The correlations and resultant p values from the
univariate assessments were analyzed for possible inclusion into a multiple regression model
for prediction of the pharmacokinetic parameters of interest. All data that failed normality
testing were transformed by various functions to ensure normality was attained. Model building
consisted of using multiple regression analysis with forward addition of variables as well as
backward elimination, noting any significant changes in coefficients of the primary predictors
as well as the R2 and p value resulting from the various models. The final model was selected
based on significance of each variable on predicting the dependent variables in the model as
well as the overall R2. Race (white and non-white) and gender (female and male) were coded
as 1 and 2, respectively.
Comparisons between clinical groups based on urinary protein excretion (< 1 g/day vs ≥ 1 g/
day), serum albumin (< 4 g/dL vs ≥ 4 g/dL), age (< 40 yrs vs ≥ 40 yrs), race (white vs nonwhite),
and gender (female vs male) were analyzed by the nonparametric Mann Whitney Test. Upon
review of our data, it was not possible to compare Clcr groups as there was no meaningful cut-
point value for evaluation.
Results
A total of 18 biopsy-confirmed lupus nephritis patients completed 21 full twenty-four hour
MPA/MPAG pharmacokinetic evaluations. We report the results for the 18 discrete patients.
The patient demographic composition included age 36 ± 9 years, 83% female, 60% non-
Caucasian, and weight 82.3 ± 22 kg. The non-Caucasian patients consisted of 7 African
American, 2 Asian, and 2 Native American. All patients were receiving the mycophenolate
mofetil prodrug of MPA (Cellcept®, Roche). The average MPA daily dose was 1860 ± 764
mg and this was represented by twice daily dosing in all but one patient who received 1000
mg three times daily. The distribution of doses given twice daily were 500 mg (n = 6), 750 mg
(n = 1), 1000 mg (n = 7), and 1500 mg (n = 4). Clcr was used as the assessment of GFR in this
study. 13 The mean (± standard deviation) clinical laboratory results at baseline were serum
creatinine 1.1 ± 0.8 mg/dL, UP:Cr 1.3 ± 2.2, Clcr 114 ± 49 mL/min, and serum albumin 3.9 ±
0.4 g/dL. Fifty percent (n = 9) of patients were receiving concomitant glucocorticoids, with a
mean ± SD daily dose of 11.4 ± 8.9. No other immunosuppressants were prescribed. Two
patients were prescribed oral contraceptives.
MPA Pharmacokinetics
A representative concentration vs time profile for steady state MPA and MPAG concentrations
in our lupus nephritis patients is presented in Figure 1. The mean (± standard deviation)
pharmacokinetic parameters for patients with lupus nephritis are provided in Table 1. In order
to eliminate differences secondary to body size, the oral clearance (Cl/F) data was adjusted to
a 70 kg patient based on a scaling method that uses a power of 0.75. 14 The Cl/F of 343 ± 200
mL/min suggests that MPA is a moderate extraction ratio drug whose metabolism would be
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impacted by changes in unbound fraction. While the mean percentage of free MPA was 2.6 ±
1.9, five patients (28%) had free MPA percentages that were greater (range 2.9 to 6.3%). The
mean MPA area under the plasma concentration time curve (AUC 0-12) in our lupus patients
was above the range of 30 to 60 mg hr/L recommended in the first six months post renal
transplant, 15 with 39% of patients exceeding and 22% failing to achieve this range.
Examination of the AUC 6-12 to the AUC 0-12 suggested that recycling accounted for 37% (±
16%) of the AUC reflected from the first daily dosing interval.
The mean MPA trough (Ctr) at 12 hours exceeded the range of 1.0 to 3.5 mcg/mL that is
recommended in transplant patients 15, with 28% of patients below and 33% above this target,
respectively. The Ctr that resulted after the first 12 hours was ~20% less than the Ctr following
the second dosing interval, however the difference was not significant. The time to maximal
concentration (Tmax) varied in the range of 0.5 to 8 hours and would not have been appreciated
in shortened sampling schemes. A three hour AUC profile would have under-represented
exposure over the dosing interval.
As suggested previously 2, the clearance of MPA is primarily the result of systemic metabolism
to MPAG. The renal clearance (Clr) for MPA represented ~ 1% of the Cl/F. The Clr of
nonmetabolized MPA was 1.8 ± 1.4 mL/min, which was ~ 2% of the Clcr in the evaluated
patients. The kidneys contributed to the excretion of 1% of the total MPA dose, assuming all
MPAG formed was via the liver. The amount of MPA in the urine over the 0-12 hour interval
(4.8 ± 3.3 mg) was ~25% less than the amount in the 12-24 hour interval (6.5 ± 9.1 mg), despite
the dosages being consistent, but this was not significant. The Clr was similar between the 0-12
hour and 12-24 hour dosing intervals.
MPAG Pharmacokinetics
The MPAG pharmacokinetic results are presented in Table 1. The MPAG Ctr after the first 12
hours was ~15% less than the Ctr following the second dosing interval. A calculated AUC ratio
of MPAG to MPA resulted in a metabolic ratio (MR) of 7.1 ± 4.8.
The renal clearance of MPAG was 53.5 ± 52.3 mL/min, which was 44% of the Clcr. The
kidneys contributed to the elimination of 96% of the total MPA dose through excretion of the
metabolite, MPAG. Hence, the kidneys were responsible for eliminating ~97% of the total
dose of MPA. The remaining MPA was likely eliminated secondary to excretion of the acyl
MPAG metabolite by the kidneys (not measured) as well as by biliary secretion of MPAG that
is not recycled. The amount of MPAG in the urine over the 0-12 hour interval (565 ± 310 mg)
was ~28% more than the amount in the 12-24 hour interval (441 ± 341 mg), despite the dosages
being consistent. The Clr was similar between the 0-12 hour and 12-24 hour dosing intervals.
Unbound Pharmacokinetics
Our patient data showed that 2.5% and 9.3% of MPA and MPAG, respectively, were unbound
in the plasma. Since the unbound MPAG was less than that reported previously 16, we reviewed
our data with normal plasma that was spiked with MPA and MPAG either alone or in
combination. The blank plasma that was spiked separately demonstrated similar percentages
to that found in our patient data. The combination drug and metabolite spiked plasma showed
an increase in unbound percentage of 4% and 11% for MPA and MPAG, respectively,
suggesting competitive binding to albumin as reported previously.
Since the normal percentage of unbound MPA is ~2%, if one aims for a total Ctr of 1.0 to 3.5
mcg/mL then an unbound target would be 0.02 to 0.07 mcg/mL. Likewise, if suggested total
AUC goals are 30 to 60 mcg h/mL, then unbound AUC goals would be 0.6 to 1.2 mcg h/mL.
Our data showed mean unbound Ctr levels (0.1 mcg/mL at 12 and 0.13 mcg/mL at 24 hours)
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that were greater than suggested, with 44.4% of patients within the range. With regard to
unbound AUC, the mean exposure was greater than the upper range of 1.2 mcg h/mL in 33%
of our lupus patients.
Regression Results
Multiple regression was performed to determine which clinical factor (UP:Cr, Clcr, serum
albumin, age, race, gender, steroid dose) had the most effect on pharmacokinetic parameters
for MPA (Clr, Cl/F, AUC 0-12, AUC 6-12) and MPAG (Clr, AUC 0-12). MPAG clearance
parameters were included as increased MPAG may result in enhanced recycling and subsequent
increases in MPA exposure. Models were constructed by forward selection and backward
elimination schemes employing the pharmacokinetic parameter as the Y factor and clinical
variables as the X factors. AUC6-12 was also included as an X factor when Clr variables were
assessed. The Clcr and serum albumin were the two clinical parameters contributing to MPA
Cl/F. Ln MPA Cl/F = 5.3585 + 0.0092 (Clcr) − 0.0776 (ranked serum albumin), R2 51.1%, p
= 0.0195; Clcr p = 0.0265, serum albumin p = 0.0586. The regression equation for MPA
AUC 0-12 demonstrated similar results, which is expected given the reciprocal relationship
between Cl/F and AUC 0-12. For the MPAG Clr analyses, the AUC 6-12 was consistent in
models that controlled for either gender or age. These two models were: 1) Ln MPAG Clr =
6.6009 − 1.3519 (gender) − 0.5257 (ln AUC 6-12), R2 39.9%, p = 0.0282; race p = 0.0405, ln
AUC 6-12 p = 0.0687, and 2) Ln MPAG Clr = 13.1896 − 2.2901 (ln age) − 0.5105 (ln
AUC 6-12), R2 39.9%, p = 0.0300; ln age p = 0.0434, ln AUC 6-12 p = 0.0776. No significant
predictors of AUC6-12 or Clr for MPA were found.
Comparison Between Groups Based on Clinical Laboratories
Given the importance of albumin in the regression model for Cl/F and AUC0-12 and the
prevalence of increased Ur:Cr in glomerulonephritis patients with reduced serum albumin
concentrations, we wanted to explore the differences in PK parameters by distinct clinical
groupings. (Table 2) UP:Cr was selected as a clinical variable secondary to the high plasma
protein binding characteristics of MPA and MPAG. It is conceivable that highly protein bound
drugs may be eliminated in the urine bound to protein in patients with proteinuria and/or they
may be preferentially eliminated by metabolism secondary to increased unbound fraction. A
cut-point value of 1 g/day was selected based on the premise that UP:Cr less than 1 g/day would
be less likely to alter PK. The MPA data shows that Cl/F was significantly increased (790 mL/
min vs 305 mL/min, p = 0.0464) and Ctr12 and AUC 0-12 were both significantly reduced in
the high protein excretion group (0.88 mcg/mL vs 5.0 mcg/mL; p = 0.012 and 33.2 mcg h/mL
vs 91.9 mcg h/mL; p = 0.018, respectively).
Since MPA and MPAG are highly bound to serum albumin, albumin was also selected for
evaluation. (Table 2). Several findings of this analysis were of borderline significance. The
MPA Clr was found to be increased nearly 2-fold in the low serum albumin group (p = 0.073).
This finding would be expected given that renal clearance would be directly related to Clcr as
well as the unbound fraction of MPA. Clunbound was found to be increased in the low albumin
group and this finding was of borderline significance (p = 0.051). Although the renal clearance
was enhanced 2-fold, the overall contribution of the kidneys to clearance was low given that
only 3% of a MPA dose is normally eliminated unchanged in the urine. 16 MPAG Clr was
increased in patients with reduced albumin (p = 0.053), reducing the amount of MPAG
available for recycling to MPA and potentially leading to reduced MPA exposure. With regard
to MPA AUC values, we found slightly increased MPA AUC 0-12 in our high albumin group
(p = 0.128), reflecting the reciprocal changes in Cl/F.
The differences in pharmacokinetic variables between age grouping (< 40 years vs ≥ 40 years),
race (white vs nonwhite), and gender (female vs male) were also evaluated (data not shown in
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Table 2). The MPA MRT was found to be greater in younger patients (21.6 hrs vs 8.23 hrs;
p=0.066), but this did not result in a significant p value. Additionally, the MPAG Clr 0-12 was
found to be increased 6-fold in females as opposed to males (66.5 mL/min vs 10.7 mL/min; p
0.047). The Clcr, however, was only ~21% greater in females than males.
Discussion
Our study is the first published report that has focused on describing the pharmacokinetic
disposition of MPA and its metabolite MPAG after chronic therapy in patients with lupus
nephritis. Additionally, in order to achieve clinical relevance to our work, we have described
relevant patient laboratory data that were found to portend variations in pharmacokinetic
disposition. Our multivariate regression assessments for prediction of Cl/F and AUC0-12
implicated serum albumin and Clcr as the main contributors. Although there is some degree
of correlation between serum albumin and UP:Cr, there is also a fair amount of variability
between the two measures in individual patients. The combined, correlative contribution of
UP:Cr and serum albumin cannot, however be fully evaluated. Hence, it is prudent to assess
both the serum albumin and UP:Cr when evaluating initial dosing for highly protein bound
drugs such as MPA. The multivariate regression assessment of MPAG Clr determined that log
AUC6-12 was contributing with gender and age also contributing equally, although in a separate
fashion.
The resulting MPA PK parameters for patients with lupus nephritis appear to be comparable
with that what has been reported for renal transplant recipients, with the exception of Cl/F,
which is up to 2 -fold greater in the lupus nephritis population. Reasons for enhanced Cl/F
include increased systemic metabolism secondary to either up-regulated glucuronidation
(single nucleotide polymorphisms in the UGT1A9 promoter or steroids), increased MPA
unbound fraction (available for hepatic extraction/metabolism), or enhanced renal excretion.
Regarding glucocorticoids, patients receiving concurrent steroids had similar Cl/F estimates
as patients who were not receiving steroids. Also, steroid dose did not contribute to the Cl/F
in the regression analysis. We are currently evaluating the contribution of genotype as a factor
in altering MPA clearance. The unbound fraction, implicated as a variable leading to increased
drug availability for metabolism is important in our patients given that 40% had albumin
concentrations that were < 4 g/dL. The regression analysis for Cl/F implicated serum albumin
as a predictive variable.
Enhanced renal clearance could occur secondary to increased free drug available or due to loss
of protein bound MPA with the urinary protein, both cases resulting in an increase in Cl/F.
However, when we evaluated Clr between patients with UP:Cr < 1 g/day and those with UP:Cr
≥ 1 g/day, the Clr results were similar. It is plausible that the magnitude of difference in Clr
was under-appreciated based on our selected cut-point for UP:Cr of 1 g/day. Further review of
our data shows a confounding effect of serum albumin levels; while 29% of our UP:Cr < 1 g/
day had low albumin levels, 75% of our UP:Cr ≥ 1 g/day had low albumin levels. A previous
study of 16 autoimmune disease patients (containing six lupus erythematosis patients) who
received 1 g MPA every 12 hours reported a mean MPA AUC 0-12 of 70.6 ± 28.7 mg h/L,
which was comparable to our study. 17 However, it is not clear whether the previous study
normalized AUC data to weight or body size to enable appropriate assessments. The MPAG
AUC 0-24 (2017.2 ± 1124) was 2-fold higher than what would have been predicted in our study
based on extrapolation of the AUC 0-12 data. MPAG is minimally active pharmacologically
and it is important in enterohepatic recycling and MPA exposure. While it was expected that
Clcr would predict the MPAG Clr secondary to MPAG being a polar metabolite that is primarily
excreted by the kidneys, our distribution of kidney function did not encompass late stage CKD
patients to enable a display of these relationships. Previous clearance data from renal transplant
patients has shown MPAG plasma clearance to be highly correlated (R2 0.86) with glomerular
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filtration rate (Clcr) and the mean Clr values for MPAG in patients with mild, moderate and
severe kidney disease were reported as 21.7, 10.0, and 5.0 mL/min, respectively. 18 Hence, a
patient with severe kidney disease could have a 4-fold reduction in MPAG clearance, resulting
in an increase in MPA AUC through recycling. Our regression model suggested that log
AUC6-12 along with log age and gender were predictors for MPAG Clr. An increase in recycling
AUC predicted a reduction in Clr of MPAG since less drug would be available as the polar,
renally excreted metabolite. An increase in age predicted a decrease in MPAG Clr, which would
support (indirectly) a role of Clcr. Most of our patients spanned the second to the fourth decade
and thus the effects of age on Clcr were not appreciated. Refinements and validation of our
model will require addition of representative patients with more severe reductions in Clcr to
fully understand the role of renal function.
A study in renal transplant recipients used a multivariate analysis and demonstrated that 24%
of the MPA Cl/F could be explained by proteinuria (yes/no), Clcr, and diabetes mellitus. 19
Our data showed that 51% of MPA Cl/F could be explained by serum albumin and Clcr, two
readily measured clinical laboratories. The contribution of Clcr to MPA Cl/F was unexpected
given the low percentage of MPA (1-3%) that is normally excreted by the kidneys. However,
patients with diminished Clcr have been documented to exhibit decreased hepatic metabolism
postulated to be due to the CKD state itself or the effect of CKD on the accumulation of
endogenous substrates. 20 In subjects with both decreased albumin and decreased Clcr, the
AUC lowering effect of reduced albumin (more drug available for metabolism) may be
balanced by an increased AUC effect secondary to a reduced Clcr. 21-22 Along another
pathway, states of inflammation can have variable effects on drug metabolizing enzymes and
transporters. 23-24
Regression models for a quantitative prediction of the Cl/F based on the serum albumin and
Clcr, when validated, could be used to guide dosage regimens. For example, in our current
model, for each 20 mL/min decrease Clcr, one would expect a decrease in Cl/F of about 30
mL/min assuming a stable serum albumin of 4.4 g/dL and an increase of about 180 mL/min
assuming a concomitant reduction in the serum albumin to 2.9 g/dL. Hence, the effects of
moderate reductions in serum albumin would have fairly significant effects on increasing Cl/
F versus moderate reductions in Clcr. Since increases in proteinuria often result in concomitant
reductions in serum albumin, the combined contributions could enhance the Cl/F of MPA even
further. However, more patients with significant proteinuria are needed to provide a more
definitive conclusion regarding the contribution of proteinuria to Cl/F for MPA. Although
requiring additional validation, the regression equation for AUC0-12 could enable calculations
of dosage modifications depending on the targeted AUC 0-12 with the assumption of linearity
within the clinically obtained plasma concentrations.
While we report the contribution of serum albumin and Clcr (via Clcr) to MPA clearance, there
are some limitations to our research. As noted previously, our patients had relatively preserved
Clcr, with only three patients presenting with more severe kidney disease (stages 2 and 3). The
full contribution of reductions in Clcr to alterations in clearance would require assessment
across the spectrum of kidney disease. Similarly, since only two patients in our dataset were
nephrotic (UP:Cr > 3.5 g/d), the full contribution of UP:Cr to clearance may actually be under-
recognized based on our data with less significant degrees of proteinuria. Additionally, the
combined role of albumin and urinary protein to elimination of highly bound drugs in patients
with glomerular diseases requires rigorous assessments. Future analyses of our data include
assessment of the contribution of genotype for drug metabolizing enzymes and transporters to
drug clearance and outcomes and analysis of the contribution of Ctr and AUC to patient
outcomes. We hope to better define appropriate concentration or exposure targets for lupus
nephritis patients.
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MPA therapy in lupus nephritis patients, as opposed to use in renal transplantation is further
complicated by urinary protein excretion and hypoalbuminemia, in addition to altered Clcr.
Serum albumin and Clcr appear to be the primary contributors to clearance estimates of MPA
and should be accounted for when dosing MPA. Similarly, clinical changes that are associated
with either response to therapy or progression of disease may necessitate future adjustments
to therapy to maintain efficacy and/or reduce toxicity. MPA therapy individualization is
possible in lupus nephritis and the results of such interventions require prospective
assessments. The acceptable AUC target for MPA therapy will need to be defined specifically
for patients with lupus nephritis to enhance clinical outcomes.
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Figure 1 shows a representative plasma concentration versus time profile for mycophenolic
acid (MPA) and its glucuronide metabolite (MPAG) over a 12 hour dosing interval.
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Table 1
Pharmacokinetic Parameters in Patients with Lupus Nephritis
Mycophenolic Acid Parameters
Tmax (hrs) 1.69 ± 1.86
Cmax (mcg/mL)* 21.0 ± 16.2
Ctr12 (mcg/mL)* 4.06 ± 5.15
Lambda (hr-1) 0.11 ± 0.07
MRT (hrs) 16.3 ± 19.9
AUCMPA 0-12 (mg hr/L)# 78.8 ± 74.1
AUCMPA 6-12 (mg hr/L)# 33.2 ± 39.0
MPA Cl/F (mL/min)+ 343 ± 200
MPA Clr 0-12 (mL/min)+ 1.85 ± 1.42
Ae 0-12 (mg) 4.81 ± 3.34
Ae 12-24 (mg) 6.53 ± 9.10
MPA free (%) 2.56 ± 1.97
Mycophenolic Acid Glucuronide Parameters
Tmax (hrs) 3.36 ± 3.56
Cmax (mcg/mL)* 55.1 ± 42.7
Ctr12 (mcg/mL)* 28.2 ± 25.2
Lambda (hr-1) 0.08 ± 0.05
AUCMPAG 0-12 (mg hr/L)# 518 ± 460
MPAG:MPA 7.09 ± 4.76
MPAG Clr 0-12 (mL/min)+ 53.5 ± 52.3
Ae 0-12 (mg) 656 ± 310
Ae 12-24 (mg) 441 ± 341
MPAG free % 9.30 ± 5.23
Free Mycophenolic Acid Parameters
Cmax (mcg/mL)* 0.44 ± 0.54
Ctr12 (mcg/mL)* 0.10 ± 0.15
Ctr24 (mcg/mL)* 0.13 ± 0.25
AUCMPA 0-12 (mg hr/L)# 1.76 ± 2.60
MPA Cl/F (L/min)+ 27.4 ± 30.5
*
normalized to a 1000 mg dose
+
scaled to a body size of 70 kg using 0.75 power
#
dose-normalized to 1000 mg and weight normalized to 70 kg
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